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Abstract: Transvaginal ultrasonography (TVS) is an integral part of all major ovarian cancer 
screening trials. TVS is accurate in detecting abnormalities in ovarian volume and morphology, 
but is less reliable in differentiating benign from malignant ovarian tumors. When used as the 
only screening test, TVS is sensitive, but has a low positive predictive value. Therefore, serum 
biomarkers and tumor morphology indexing are used together with TVS to identify ovarian 
tumors at high risk for malignancy. This allows preoperative triage of high-risk cases to major 
cancer centers for therapy while decreasing unnecessary surgery for benign disease. Ovarian 
cancer screening has been associated with a decrease in stage at detection in most trials, thereby 
allowing treatment to be initiated when the disease is most curable.
Keywords: ovarian cancer, ultrasound, screening, serum Ca-125
Introduction
Ovarian cancer remains a major health problem worldwide, with over 225,000 new 
cases and 140,000 deaths reported annually.1,2 Symptoms associated with ovarian 
cancer are often nonspecific, and the majority of patients continue to present with 
advanced disease, where the cost of treatment is high and the survival rate is low.3,4 
Although early stage ovarian cancer is highly curable with conventional treatment, it 
is estimated that only 15% of patients have their disease confined to the ovary at the 
time of diagnosis.5
Many investigators believe that earlier detection is the most effective means to 
reduce ovarian cancer mortality. For example, it has been estimated that if 75% of 
ovarian cancer cases (rather than the present 25%) could be detected at stage I or II 
disease, the number of deaths from this disease would be reduced by half.6
Screening is defined as the application of a test or combination of tests to an 
asymptomatic at-risk population in an attempt to detect a disease at an earlier and 
more curable stage. A disease that theoretically should benefit from screening has the 
following characteristics: 1) it should be prevalent in the population to be screened, 
2) it should be a major health problem, 3) it should have a significant preclinical stage 
during which detection through screening is possible, and 4) it should be significantly 
more curable when diagnosed at an early stage than at an advanced stage.7
Ovarian cancer fulfills many of these characteristics, but the duration of its pre-
clinical phase is variable and often unknown. Ovarian cancer is the fifth-leading 
cause of cancer mortality in females in the US, and often affects women who are well 
educated and of upper-socioeconomic status. Although this disease is not prevalent 
International Journal of Women’s Health 2014:6submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
26
van Nagell Jr and Hoff
in the general population, it is significantly more common 
in women over 50 years of age (incidence 55 in 100,000),8,9 
and in those with a documented family history of breast or 
ovarian cancer. In the US, for example, the lifetime risk of 
ovarian cancer increases from 1.2% in the general population 
to 5.0% in women who have one first-degree relative with the 
disease.10 The estimated lifetime risk of ovarian cancer may 
be as high as 46% in women who are BRCA1-positive, and 
20% in women who are BRCA2-positive.11 For this reason, 
all women over the age of 50 years or those over the age of 
25 years with a documented family history of ovarian cancer 
usually are eligible to participate in screening trials.
The pathogenesis of ovarian cancer and therefore the 
duration of its preclinical stage is variable. Traditionally, 
epithelial ovarian cancers were thought to arise through 
changes in the ovarian surface epithelium-lining inclusion 
cysts formed at the time of ovulation.11,12 Recently, Crum 
et al reported that certain epithelial ovarian cancers may 
arise from the epithelium of the distal fallopian tube. Tubal 
intraepithelial carcinoma was noted in the distal fimbria of 
57%–100% of women with BRCA1 or BRCA2 mutations 
and in 47% of patients with primary peritoneal cancer.14,15 
p53 mutation analysis was identical in the tubal intra-
epithelial carcinoma and remote invasive tumors from the 
same patient, supporting a genetic link between the two.15 
Kurman and Shih have proposed that there are two types of 
epithelial ovarian cancers.16 Type I cancers are low-grade 
serous or endometrioid ovarian malignancies, probably aris-
ing from neoplastic transformation of the ovarian surface 
and  epithelium. Type I cancers are genetically similar to 
epithelial ovarian tumors of low malignant potential, and 
have a prolonged preclinical phase during which screening 
intervention should be effective. Type II cancers are high-
grade, poorly differentiated, serous tumors, many of which 
arise from the tubal epithelium. These tumors have a shorter 
preclinical phase, and may require more frequent screening 
to achieve early detection.
Finally, early stage ovarian cancer is significantly more 
curable than late-stage ovarian cancer. For example, the 
5-year survival of patients with stage I epithelial ovarian can-
cer is approximately 95% at major cancer centers, compared 
to 30% for patients with stage III disease.17 Furthermore, 
two-thirds of patients with advanced-stage ovarian cancer 
who are alive at 5 years have recurrent cancer, so the long-
term cure rate for these patients is only 10%.
A screening test also must meet certain standards if 
it is to be effective. An optimal screening test should be 
easy to perform, time-efficient, and well accepted by those 
being screened. Also, it should be inexpensive and associated 
with few side effects, so that screening compliance is high. 
Finally, the results of the test should be easy to interpret, with 
minimal interobserver variation. To be effective, a screening 
test should be sensitive, specific, and associated with a high 
positive predictive value (PPV) and a high negative predic-
tive value (NPV). The statistical definitions used in ovarian 
cancer screening are presented in Table 1. A true-positive 
screen is defined as histologically confirmed ovarian cancer 
in a woman with an abnormal test. In contrast, a true-negative 
screen is the absence of ovarian cancer for at least 12 months 
after a normal test. A false-negative screen is the occurrence 
of histologically confirmed invasive ovarian cancer within 
12 months after a normal scan, whereas a false-positive 
screen is the absence of ovarian cancer in a patient with 
a positive screen. Regular screening should lower stage 
at detection and increase disease-specific ovarian cancer 
survival. Finally, ovarian cancer mortality should be lower 
in the screened population than in a similar population of 
unscreened women.7
Transvaginal sonography (TVS) is an integral part of 
virtually every ovarian cancer screening algorithm, whether 
it is used as the initial screening test or as a secondary test 
in women with an elevated biomarker profile. TVS, per-
formed with a 5–7.5 mHz vaginal probe, generates accurate 
ovarian images that can be used to detect early changes in 
ovarian morphology and volume not appreciated on clinical 
 examination. Ovarian volume is calculated using the prolate 
ellipsoid formula (length × width × height × 0.523). Criteria 
for ovarian abnormality vary according to each screening 
trial, but usually involve both volume and morphology. 
 Ovarian volumes .20 cm3 in premenopausal women and 
.10 cm3 in postmenopausal women are defined as abnormal, 
because these values are more than two standard deviations 
above the published mean ovarian volumes for normal women 
in these two groups.18 Morphologic abnormality is based on 
the presence of solid areas or papillary projections from the 
Table 1 Statistical definitions used in ovarian cancer screening
Term Screen Findings
TP Positive Histology confirms ovarian cancer
FP Positive Benign ovarian histology
TN Negative No evidence of disease 12 months after  
negative screen
FN Negative Ovarian cancer diagnosed within 12 months 
of negative screen
Notes: Sensitivity, TP/(TP + FN); specificity TN/(TN + FP); positive predictive value, 
TP/(TP + FP); negative predictive value, TN/(TN + FN).
Abbreviations: FN, false negative; FP, false positive; TN, true negative; TP true 
positive.
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cyst wall in a complex cystic ovarian tumor or a solid  ovarian 
tumor with an abnormally increased volume (Figure 1). 
There are a number of quantitative indexes relating ovarian 
tumor morphology to risk of malignancy.19–21 The tumor-
morphology index reported by Ueland et al21 is illustrated in 
Figure 2. Numeric scores (1–5) are given in the categories of 
tumor volume and tumor morphology, with a combined total 
score ranging from 0 to 10. This index was applied to a study 
population of 442 ovarian tumors, which included 53 ovarian 
cancers.21 Using a morphology-index value $5 as indicative 
of malignancy was associated with the following statistical 
parameters: sensitivity 98%, specificity 81%, positive predic-
tive value 41%, and negative predictive value 99%. Recent 
data suggest that unilocular ovarian cysts or septated ovarian 
cysts are rarely if ever malignant.22,23 Long-term follow-up 
of more than 3,200 unilocular cystic ovarian tumors ,10 cm 
diameter detected by screening revealed that the risk of malig-
nancy in these tumors was essentially nonexistent.22 Women 
with these tumors were  followed with periodic ultrasound 
examinations for an average of 6.3 years, and none developed 
ovarian cancer. In a subsequent investigation,23 2,870 septated 
cystic ovarian tumors detected by screening were followed 
every 4–6 months by TVS for an average of 6.4 years. Thirty-
eight percent of these tumors resolved spontaneously, and no 
patient developed ovarian cancer. Therefore, unilocular or 
septated ovarian cysts ,10 cm diameter detected by screen-
ing are no longer considered abnormal and are not removed 
surgically.
For screening to be effective, there should be a stan-
dard evaluation and treatment algorithm applied to all 
women with a screen-detected ovarian abnormality. The 
evaluation algorithm used in the University of Kentucky 
Screening Trial is illustrated in Figure 2. Women with an 
ovarian abnormality on ultrasound screening are asked to 
return for repeat sonography in 4–6 weeks. If the ovarian 
abnormality is persistent on repeat sonography, a serum 
Ca-125 is obtained and ovarian tumor indexing is performed. 
Unilocular or septated cystic ovarian tumors ,10 cm in 
women with a normal serum Ca-125 are followed without 
surgery by ultrasound examinations at 6-month intervals. 
Women with a persisting solid or complex ovarian mass 
and an elevated or rising serum Ca-125 level are advised to 
have laparoscopic tumor removal. Patients with an ovarian 
malignancy on frozen-section histologic evaluation at the 
time of laparoscopy undergo immediate laparotomy with 
tumor cytoreduction and staging. Recently, McDonald et al24 
evaluated the combination of tumor morphology generated 
from sonographic images and serum Ca-125 as a means to 
predict risk of malignancy in ovarian tumors. After multi-
variable regression analysis, women with an ovarian tumor 
having complex or solid morphology and a serum Ca-125 
value greater than 35 u/mL were defined as being at high risk 
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Figure 1 Sonographic images of benign and malignant ovarian morphology. Numeric representation of increasing morphologic complexity is noted in the first column.
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Figure 2 The University of Kentucky Ovarian Tumor Morphology Index.
Notes: Copyright © 2003, with permission from elsevier. Reprinted from Ueland FR, DePriest PD, Pavlik eJ, et al. Preoperative differentiation of malignant from benign 
ovarian tumors: the efficacy of morphologic indexing and Doppler flow sonography. Gynecol Oncol. 2003;91:46–50.21
for ovarian cancer. This definition of high risk was evaluated 
in 395 patients undergoing surgery for an ovarian tumor, 
118 of whom had ovarian cancer. This definition had a PPV 
of 84.7%, an NPV of 92.4%, and correctly identified 77.3% 
of patients with stage I and II ovarian cancer and 98.6% of 
patients with stage III and IV ovarian cancer.
Analysis of ovarian cancer  
screening trials
There are four large ovarian cancer screening trials reported 
that have TVS as a major component of the screen-
ing  algorithm (Table 2). The Prostate, Lung, Colorectal 
and Ovarian (PLCO) trial in the US was a randomized 
controlled trial of 78,216 women aged 55–74 years assigned to 
receive either annual screening with TVS and serum Ca-125 for 
4 years or their usual gynecologic care.25,26  Ultrasound findings 
considered abnormal included: 1) an ovarian volume .10 cm3, 
2) an ovarian cyst volume .10 cm3, 3) any solid area or pap-
illary projection extending into the cavity of a cystic ovarian 
tumor of any size, or 4) any mixed (solid and cystic) com-
ponent within a cystic ovarian tumor. Participants and their 
physicians received written notification of screening results 
within 3 weeks of testing. However, the evaluation and treat-
ment of each patient with a screening abnormality was left 
to the discretion of her local physician. Seventeen ovarian 
tumors of low malignant potential were detected, but were not 
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Table 2 Ovarian cancer screening trials utilizing transvaginal sonography
Screening  
trial
Years Control  
group
Study  
design
Screening  
test(s)
Number  
screened/  
detected
Invasive  
cancers
Stages I  
and II
Stages III  
and IV
Stage  
shift
Survival 
benefit
PLCO (USA)26 1993–2001 (+) Randomized  
control
Ultrasound  
Ca-125
34,253 212 47 (22%) 163 (77%) (-) (-)
UKC-TOCS  
(UK)27
2001–2005 (+) Randomized  
control
Ultrasound  
Ca-125
50,078 34 47% 53% (+) Analysis 
pending
Ultrasound  
alone
48,230 24 50% 50% (+) Analysis 
pending
Multicenter  
(Japan)28
1985–1999 (+) Randomized  
control
Ultrasound  
Ca-125
41,688 27 67% 33% (+) Analysis 
pending
University  
of Kentucky  
(USA)29
1987–2013 (+) Population  
control
Ultrasound 41,413 53 68% 32% (+) (+)
Abbreviations: PLCO, Prostate, Lung, Colorectal and Ovarian; UKC-TOCS, UK Collaborative Trial of Ovarian Cancer Screening.
considered as ovarian malignancies in the analysis presented. 
Seventy-one percent of women whose ovarian cancers were 
detected by TVS alone had stage I or II disease, but the PPV 
of TVS varied from only 0.7% to 1.6% for each year of the 
trial, and the ratio of  surgeries to screen-detected ovarian can-
cers was 19.5 to 1. There was no evidence of a shift to earlier 
stage disease associated with screening in this trial, and sur-
vival rates were similar in the screening and usual-care arms. 
Unfortunately, there was no uniform evaluation and treatment 
algorithm followed in patients with screen-detected cancers in 
this trial; patients in the screening arm could be treated up to 
9 months after detection and remain in the study.
The largest ongoing ovarian screening trial is the UK 
 Collaborative Trial of Ovarian Cancer Screening (UKC-
TOCS).27 In this trial, a total of 202,638 postmenopausal 
women ages 50–74 years were randomly assigned to 1) no 
treatment (n=101,359), 2) annual Ca-125 screening with 
TVS as a second-line test (n=50,078), or 3) annual screening 
with TVS alone (n=48,230). Ovarian volume was measured 
using the prolate ellipsoid formula as previously mentioned, 
and ovarian morphology was classified as normal, a simple 
cyst, or complex ovarian mass including any nonuniform 
echogenicity. Ascites was noted when there was a maximum 
vertical fluid measurement $10 mm. An abnormal scan was 
defined as the presence of complex morphology in one or 
both ovaries, a simple cyst .60 cm3 in volume, or ascites. A 
woman with an abnormal primary screen had a repeat ultra-
sound examination in 6–8 weeks, and if the repeat scan was 
abnormal, she was referred for clinical  assessment. Clinical 
assessment included a serum Ca-125, repeat TVS, Doppler 
studies, and computed  tomography/ magnetic resonance imag-
ing scans of the abdomen and  pelvis. Of the 48,230 women 
who underwent ultrasound alone 2,774 (5.7%) were classified 
as abnormal and had a repeat scan. There was a persisting 
ovarian abnormality on the repeat scan in 1,824 women. 
These women then underwent clinical assessment, and 845 
(1.8%) had surgery. Forty-five of these women had malig-
nant neoplasms of the ovary, 23 of which were borderline 
tumors. The ratio of surgeries to screen detected cancers in the 
ultrasound-alone arm of this trial was 18.8 to 1. Fifty percent 
of primary invasive  ovarian or tubal malignancies detected 
by ultrasound screening alone had stage I or II disease versus 
26% in the control cases detected clinically, so screening 
produced a significant increase in the detection of early stage 
ovarian malignancy. In the multimodality-screening arm of 
this trial, ultrasound was performed only in women whose 
Ca-125 values placed them in an intermediate or high risk for 
ovarian cancer. Of the 50,078 women in the multimodality-
screening arm, 409 (0.8%) had TVS, and 97 underwent 
surgery after clinical assessment. Thirty-four patients had 
ovarian cancer, 16 of whom (47%) had stage I or II disease. 
The ratio of surgeries to screen-detected cancers in this arm 
of the trial was 2.8 to 1. The UKC-TOCS trial is ongoing, 
and the effect of screening on ovarian cancer mortality will 
be published after data analysis is complete.
The multicenter ovarian cancer screening trial in Japan28 
was a prospective randomized trial conducted between 1985 
and 1999 in which asymptomatic postmenopausal women 
were assigned either to a screening arm (n=41,688) or a con-
trol arm (n=40,799). Women in the screening arm received an 
annual pelvic examination, an annual pelvic ultrasound, and 
a serum Ca-125. During the ultrasound examination, each 
ovary was measured in three dimensions, and ovarian mor-
phology was documented. Ultrasound findings were  classified 
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as follows: 1) normal ovary, largest diameter ,4 cm with nor-
mal morphology, 2) benign impression, ovarian length $4 cm 
with simple morphology, or 3) malignant impression, ovar-
ian length $4 cm with complex  morphology. Management, 
including surgical intervention, was at the discretion of a 
gynecologic oncologist. A total of 103 patients thought to 
be at high risk for ovarian cancer on the basis of ultrasound 
findings were evaluated by a gynecologic oncologist, and 
64 underwent surgery. Twenty patients were found to have 
primary ovarian cancer, and ten had metastatic disease to the 
ovary. As in all the screening trials other than the PLCO trial, 
regular ultrasound screening was associated with a decrease 
in stage at detection. In the Japanese trial, 63% of ovarian 
cancer patients detected by screening had stage I disease 
versus 38% in the control arm. Likewise, optimal tumor 
debulking was achieved more frequently in women whose 
ovarian cancer was detected by screening. Assessment of the 
long-term effect of screening on ovarian cancer mortality is 
presently in progress.
The University of Kentucky Ovarian Cancer Screening 
Trial (UKOCS) has been in progress since 1987, and has 
enrolled 41,413 women.29 Eligibility criteria include all 
women over the age of 50 years and women above 25 years 
of age with a documented family history of ovarian cancer. 
This trial does not have a “no screening” control arm into 
which women are prospectively enrolled. Rather, data con-
cerning women receiving screening is compared to a control 
population of women from the same geographic area, receiv-
ing the same treatment protocols, at the same hospital, over 
the same time period who did not receive screening. In this 
screening trial, all women with an abnormality on TVS are 
evaluated and treated according to a standard protocol (see 
Figure 2). Women with an abnormal screen have a repeat 
screen in 4 weeks. If the repeat screen is abnormal, a serum 
Ca-125 is obtained, Doppler analysis of tumor blood flow 
is performed, and tumor morphology indexing is completed 
(see Figure 3). If these studies indicate that an ovarian tumor 
is at high risk for malignancy, laparoscopic tumor removal 
is performed as soon as possible. The time between ovar-
ian tumor detection and surgical removal is designed not 
to exceed 8 weeks. To date, 53 primary epithelial ovarian 
malignancies have been detected in the UKOCS trial, 68% 
of which were limited to the ovary or pelvis (stage I or II 
disease). Twelve women developed ovarian cancer within 
Transvaginal
ultrasound screening
(TVS)
AbnormalNormal
Repeat TVS 1 year Repeat TVS 4–6 weeks
Cystic or septated tumor
<10 cm diameter, Ca-125 <35 U/mL
Abnormal
Tumor indexing, Ca-125,
color doppler sonography
Repeat TVS 6 months
Normal
Repeat TVS 1 year
Complex or
solid tumor
Diagnostic surgery
Figure 3 evaluation algorithm for women enrolled in the University of Kentucky Ovarian Cancer Screening Trial.
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12 months of a normal screen (interval cancers). Women 
whose ovarian cancers were diagnosed by screening had 
earlier-stage disease at detection (68% stage I or II disease) 
than those who did not receive screening (27% stage I or II 
disease, P,0.01). In addition, there was a substage shift 
within stage III in that more women in the screening group 
had stage IIIA disease. The 5-year survival of all women 
whose epithelial ovarian cancers were detected by screening 
including interval (false-negative) cancers was 74.8%±6.6% 
compared to 53.7%±2.3% for women with clinically detected 
ovarian cancers treated at the same institution during the 
same time period with identical surgical and chemotherapy 
protocols (P,0.01).
Cost of screening
The cost of screening varies according to the individual 
trial and the specific algorithm employed. The cost of each 
ultrasound is approximately $40 when performed in high-
volume screening centers using modern two-dimensional 
ultrasound equipment.30 Single-biomarker testing is less 
expensive than multiple-marker panels, but even the cost of 
a single Ca-125 determination varies significantly from one 
institution to another. With developing technology, every 
effort must be made to reduce the cost of biomarker testing. 
This is particularly important, since sequential biomarker and 
ultrasound testing are being utilized as a means to increase the 
PPV of screening and reduce unnecessary surgery. The cost 
of screening must be evaluated in the context of treatment 
costs for patients with ovarian cancer. Analysis of financial 
data, including inpatient, outpatient, pharmacy, and physi-
cian charges, indicates that the total cost of treatment for a 
patient with stage IIIC epithelial ovarian cancer is in excess 
of $200,000.31 Much of this cost is related to the treatment 
of recurrent ovarian cancer, which is common in patients 
initially detected with advanced-stage disease. This analysis 
did not place a financial value on years of lost productivity 
from disease-specific mortality.
Future ovarian cancer  
screening trials
Fundamental questions remain concerning who should be 
screened, the frequency of screening, and the optimal order 
of tests within a specific screening algorithm. Although 
ovarian cancer is a leading cause of cancer mortality, it is a 
relatively rare disease, occurring with an incidence of only 
55 in 100,000 in high-risk age-groups. The incidence of 
ovarian cancer is higher in postmenopausal women, women 
with a family history of ovarian cancer, and women with 
certain genetic mutations, such as BRCA1, BRCA2, and 
Lynch II syndrome. As a result, eligibility in most screening 
trials is limited to postmenopausal women or women with 
a documented family history of ovarian cancer over the age 
of 25 years. Further, epidemiologic research is needed to 
determine additional demographic and molecular genetic 
factors that predispose women in the general population 
to be at increased risk of ovarian cancer. The type and 
frequency of screening can then be designed based on an 
individual’s ovarian cancer-risk profile. As specific at-risk 
populations are defined more clearly, the cost of screening 
should decrease.
The origin of certain ovarian malignancies from the fallo-
pian tube epithelium13 may make these tumors more difficult 
to detect at an early stage. Studies are in progress to assess 
the diagnostic accuracy of advanced ultrasound in detecting 
early morphologic abnormalities in the fallopian tube, but 
the results have yet to be published. The exact frequency of 
ovarian cancers that arise from the fallopian tube epithelium 
is unknown, but future screening trials may require evaluation 
of both tubal and ovarian morphology.
TVS has been accurate in identifying minimal changes in 
ovarian volume and morphology, but has not been reliable 
in differentiating benign from malignant ovarian tumors. 
Morphology indexing (MI) has been developed as a method 
to quantitate changes in tumor morphology and relate them to 
risk of malignancy (Figure 2). Ovarian tumors without solid 
areas or papillary projections have been shown to be rarely if 
ever neoplastic, and can be followed sonographically without 
surgery. However, the histology of complex ovarian tumors 
is more difficult to predict from ultrasound images. Recently, 
serial MI has been used to distinguish benign from malignant 
ovarian tumors. MI values were found to increase with time 
in ovarian cancers, but decreased or remained stable in benign 
ovarian tumors.32 Serial MI determinations at biweekly or 
monthly intervals may be incorporated into future screening 
trials in women with persisting complex ovarian tumors as a 
means to increase PPV of screening in these patients.
Another area of recent research interest is contrast-
enhanced TVS using microbubble contrast-agent particles.33 
These particles have a dynamic response in the ultrasonic 
field, and can more accurately define tumor neovascularity. 
This technology was evaluated in a preliminary study involv-
ing 23 morphologically abnormal ovarian tumors, nine of 
which were malignant.34 There was a statistically significant 
difference in contrast-enhancement kinetics between benign 
and malignant ovarian tumors. Specifically, peak enhance-
ment, half-washout time, and area under the enhancement 
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curve were all higher in malignant ovarian tumors when 
compared to benign lesions. Using a diagnostic criterion 
of an area under the curve .787 seconds1 as indicative of 
malignancy achieved a sensitivity of 100% and a specificity 
of 96.2%. These results are interesting, and await confirma-
tion in prospective clinical trials.
It is worth reemphasizing that a standard evaluation 
and treatment protocol should be applied uniformly to all 
patients with a screen-detected ovarian abnormality. Such 
a protocol should be designed such that operative interven-
tion is recommended only in patients who after repeat test-
ing are at significant risk for ovarian cancer. Also, surgery 
should be performed in a timely fashion, preferably within 
8 weeks of diagnosis, in order to preserve the benefits of early 
 detection. Two prerequisites for a successful screening test 
are that it lower stage at detection and reduce disease-specific 
 mortality.7 TVS has been shown to lower stage at detection 
in most trials. However, it is difficult to prove that screening 
decreases ovarian cancer mortality unless an effective evalu-
ation and treatment algorithm is applied uniformly to women 
in whom screening has identified an ovarian abnormality.
Finally, the optimal combination of TVS with other 
screening tests is undergoing continued evaluation. 
 Sonography alone is unreliable in detecting primary perito-
neal cancer or ovarian cancer in which there is no volume or 
morphologic abnormality of the ovary. Therefore, some 
algorithms, such as the multimodal screening arm of the 
UKC-TOCS trial, utilize TVS as a secondary test in women 
designated as high risk on the basis of their biomarker 
 profile.27 This approach increases the PPV of TVS. For 
example, 42 of the 97 patients designated as high risk by 
biomarker profile in the UKC-TOCS trial had ovarian can-
cer at the time of surgery (PPV =43.2%). In contrast, only 
45 of 845 patients had ovarian cancer (PPV =2.3%) when 
ultrasound was used as the sole screening modality. The 
sensitivity of biomarkers in detecting early stage ovarian 
cancer is low, however, and these cancers would be missed if 
they did not produce detectable marker levels in the serum. 
Hirai et al, for example, reported that only 40% of stage IA 
ovarian cancers have an elevated serum Ca-12535. As has 
been mentioned, when TVS is used as the primary screening 
test, repeat sonography and biomarker analysis should be 
performed prior to recommending surgery, so that opera-
tive intervention can be avoided in women whose ovarian 
abnormalities are resolving spontaneously.
Although TVS has known limitations as a screening 
method for ovarian cancer, it remains an integral part of all 
screening trials. The majority of these trials have reported 
that annual screening lowers stage of detection, and there-
fore should reduce ovarian cancer mortality. Research is 
in progress to develop new diagnostic tests, which when 
combined with ultrasound will increase the accuracy and 
PPV of screening. Early detection remains of fundamental 
importance, since it allows effective treatment to be initi-
ated when ovarian cancer is most curable.
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